Verano Holdings Announces 1-for-5 Reverse Split, Eyes Major US Exchange Listing

Verano Consolidates Shares to Chase the NYSE

One day after Trulieve's historic NYSE debut, another major cannabis multistate operator will undergo its own structural transformation. Verano Holdings Corp. announced on June 1, 2026, that its Board of Directors has approved a 1-for-5 reverse stock split of its common stock, effective on or about June 11.

The math is straightforward: every five shares of outstanding Verano common stock will be combined into one share, reducing the total share count from approximately 364.4 million to roughly 72.9 million. No fractional shares will be issued — shareholders who would receive a fraction will instead get a cash payment based on fair market value.

But the strategy behind the numbers is anything but simple. Verano is positioning itself to follow Trulieve onto a major US stock exchange, a move that could reshape how institutional investors view the company and the broader cannabis MSO space.

Why Reverse Splits Matter in Cannabis

Reverse stock splits carry a stigma in traditional markets. When a struggling company consolidates shares to avoid delisting requirements, it's often interpreted as a sign of weakness. But the cannabis industry operates under fundamentally different dynamics.

Cannabis MSOs have been forced to trade on secondary markets — the Canadian Securities Exchange, the OTCQX, and similar venues — because federal illegality prevented listing on the NYSE or Nasdaq. These secondary markets typically have lower share price requirements, which means cannabis companies haven't faced the usual incentives to maintain higher per-share prices.

As Schedule III reclassification opens the door to major exchange listings, cannabis companies need to bring their share prices into ranges that satisfy listing requirements and attract institutional interest. Most major exchanges require minimum share prices — typically above $1 for Nasdaq and above $4 for the NYSE. A reverse split accomplishes this mechanically by reducing the share count and proportionally increasing the per-share price.

Verano's management stated explicitly that the consolidation is intended to "advance Verano on its path towards listing its common stock on a major U.S. stock exchange" and that it expects the split to increase institutional investor interest and access.

Verano's Position in the MSO Landscape

Verano operates in 13 states with a portfolio of over 130 retail locations. The company generated approximately $900 million in revenue in 2025 and has been improving its balance sheet through strategic refinancing — including a $195 million debt restructuring earlier this year that extended maturities and reduced interest costs.

Among the Big Five MSOs — Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, and Verano — each is taking a slightly different approach to the post-Schedule III landscape. Trulieve restructured its medical and adult-use operations to satisfy NYSE requirements. Curaleaf announced a 1-for-3 reverse split earlier this year. Green Thumb became the first MSO to file for DEA Schedule III registration.

Verano's 1-for-5 ratio is the most aggressive consolidation among the group, suggesting management wants maximum per-share price elevation to meet exchange requirements and signal institutional credibility.

The Timeline

The reverse split takes effect on or about June 11, 2026. Post-split, Verano's shares will continue to trade on the CSE under the symbol VRNO and on the OTCQX under VRNOF — but likely with adjusted prices reflecting the consolidation.

Verano has not yet announced a specific exchange or timeline for uplisting, making this a preparatory rather than confirmatory move. The company will still need to complete the application process, satisfy exchange listing standards, and potentially restructure its operations similarly to how Trulieve separated its medical and adult-use businesses.

What Investors Should Watch

For current Verano shareholders, the reverse split doesn't change the fundamental value of their holdings. Owning 500 shares at $2 is economically identical to owning 100 shares at $10. The portfolio value remains the same.

What changes is the signaling and the structural positioning. If Verano successfully uplists to the NYSE or Nasdaq, the shares gain exposure to institutional investors, analyst coverage, and index inclusion — all of which can drive meaningful changes in valuation multiples and trading liquidity.

However, investors should be aware that reverse splits without fundamental improvement can lead to post-split price erosion. The stock needs improved operating results, not just financial engineering, to sustain higher valuations. Verano's Q1 2026 results will be closely scrutinized for evidence that Schedule III tax relief (the end of Section 280E) is flowing through to the bottom line.

The broader question for the cannabis sector is whether the uplist race creates a virtuous cycle — where exchange listing drives institutional investment, which supports share prices, which enables better financing terms, which funds growth — or whether it merely concentrates attention on a few large operators while smaller companies are left behind on secondary markets.

The MSO Uplist Scorecard

As of early June 2026, the competitive positioning looks like this:

Trulieve is confirmed on the NYSE starting June 10, making it the clear first mover. Verano is executing its reverse split on June 11, positioning for a future application. Curaleaf completed a 1-for-3 reverse split earlier in 2026 and is widely expected to pursue uplisting. Green Thumb Industries filed for DEA Schedule III registration and is likely preparing its own exchange application. Cresco Labs reported Q1 2026 revenue of $151 million with improved margins under Schedule III, potentially setting the stage for its own uplist move.

The next 12 months will likely determine which MSOs join Trulieve on major exchanges — and which remain locked out. For Verano, the June 11 reverse split is the starting gun in what promises to be a defining chapter for the company and the industry.